Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme receives "complete response" letter for Clolar

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA has issued a "complete response" letter for Genzyme's sNDA for use of Clolar (clofarabine) in previously untreated older adult patients with acute myeloid leukemia, the firm announced Oct. 6. FDA's Oncologic Drugs Advisory Committee voted in September that data from a randomized, controlled trial was necessary to establish safety and efficacy in the proposed adult AML indication (1"The Pink Sheet," Sept. 7, 2009). FDA's letter recommends Genzyme conduct such a trial. Drug sponsors seeking approval for elderly AML have argued that randomized trials are difficult to conduct in the setting, and Genzyme sought approval based on a single-arm trial. The company is already conducting a randomized, placebo-controlled Phase III trial of clofarabine plus cytarabine in relapsed and refractory AML patients over 55, with results expected in 2011. Genzyme plans to meet with FDA to discuss whether the additional study may satisfy regulatory requirements. Clolar is already approved for pediatric ALL


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts